Dupilumab, a humanized monoclonal antibody targeting IL-4Rα, has shown good efficacy in type 2 inflammation-related diseases; however, its efficacy and safety in COPD treatment remain to be verified. This evidence concerns the gene IL4R and chronic obstructive pulmonary disease.